Lifeward Ltd. Ordinary Shares (LFWD)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a student of Graham and Buffett, I start with the business, not the stock story. Lifeward sells rehabilitation exoskeletons and mobility devices, a worthy field but a tiny enterprise of 81 employees. The filed record shows why the market is skeptical: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $6.6M and net income was -$11.5M, or diluted EPS -$4.12. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was just $443,000 and net income was -$10.8M. Fiscal 2025, the year ended 2025-12-31, had revenue of $1.4M and a net loss of $19.9M, while fiscal 2024, the year ended 2024-12-31, had revenue of $1.7M and a net loss of $28.9M. FairStock's Lynch category is none because the company has lost money in each of the last four years. Financial health is poor. Trailing free cash flow is -$17.1M, a FairStock FCF yield of -99.0% against the 2026-10-13 market cap of $17.3M. FairStock calculates ROE at -225.65%, ROCE at -47.26%, Piotroski at 4/9, and Altman Z-Score at -11.52. Debt/equity is 0.57, so leverage adds risk. At $6.10 on 2026-10-13, FairStock shows a P/B of 1.41 and negative P/E of -0.42. A low beta of 0.40 does not protect against business failure. On growth, FairStock shows revenue growth of 15.71%, but profit growth of -75.54%. The revenue base is erratic: fiscal Q2 2026 revenue of $6.6M rose from $5.7M in fiscal Q2 2025, the quarter ended 2025-06-30, yet fiscal Q1 2026 was only $443,000. I see no durable moat in these figures, just a cash-consuming medical-device venture. Until it shows positive margins, lower cash burn, and recurring revenue, the price looks speculative rather than Graham-cheap.

In plain English: Lifeward makes medical devices such as exoskeletons that help people with mobility problems. The business looks weak: it has lost money for years, burns cash, and the latest filed quarter showed a big loss. At $6.10 on 2026-10-13, the price looks expensive compared with those losses and cash use.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer